The Ursodeoxycholic Acid Market is being driven by Rise in number of liver transplants
The Ursodeoxycholic Acid Market is expected to grow at a CAGR of 12.9% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 550.4 million. Ursodeoxycholic acid (UDCA), a bile acid, holds significant value in the therapeutic arena for managing various liver disorders and diseases, including Primary Biliary Cholangitis (PBC) and gallstone dissolution. The global ursodeoxycholic acid market is propelled by the increasing acceptance of combination therapies in the treatment of liver diseases. These therapies involve the concurrent administration of two or more medications to amplify treatment efficacy and optimize patient outcomes. In the realm of liver disorders, the synergistic use of UDCA with immunosuppressants or steroids has been clinically proven to retard disease progression and alleviate symptoms, thereby bolstering market growth.
Get more information on Ursodeoxycholic Acid Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
205 |
Base year |
2024 |
Historic period |
2019-2023 |
Forecast period |
2025-2029 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.9% |
Market growth 2025-2029 |
USD 550.4 million |
Market structure |
fragmentation |
YoY growth 2024-2025(%) |
11.2 |
Key countries |
US, Germany, UK, China, Canada, India, Brazil, France, Japan, and Italy |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
Ursodeoxycholic acid (UDCA) is a bile acid with therapeutic applications in various liver conditions. It promotes liver cell regeneration, enhances bile acid excretion, and hinders cirrhosis progression. UDCA offers hepatotoxicity prevention against drug-induced liver injury and non-alcoholic fatty liver disease. It reduces oxidative stress, inhibits apoptosis, and regulates bile flow. UDCA improves liver function, alleviating cholestatic jaundice and intrahepatic cholestasis. Nuclear receptors and liver regeneration pathways are involved, along with drug metabolism enzymes and lipid metabolism. UDCA interacts with hepatic stellate cells, inflammation markers, fibrosis markers, liver histology, serum markers, and clinical trial outcomes.
The Ursodeoxycholic Acid (UDCA) market is a significant segment of the global pharmaceuticals industry, focusing on the production and research and development of drugs used in bile acid metabolism, cholesterol gallstones treatment, and cholestasis management. According to Technavio, the global pharmaceuticals market is projected to expand due to several factors, including the increasing aging population. By 2050, approximately one-quarter of the US and European populations are predicted to be over 60 years old. This demographic shift will increase the demand for UDCA, as it is commonly used to treat gallstone disease and liver conditions prevalent in older adults. Additionally, UDCA's role in improving hepatic bile flow and managing cholestasis makes it a crucial medication in the healthcare sector. The global pharmaceuticals market size is calculated based on the combined revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted